Axo Longevity raises $5M seed to expand preventive health membership across Europe
What's the deal? Axo LongevityDealroom has a profile for this one. Try Dealroom → has closed an oversubscribed $5 million seed round to expand its preventive health membership across Europe and beyond. The round drew MS&AD VenturesDealroom has a profile for this one. Try Dealroom →, Izou PartnersDealroom has a profile for this one. Try Dealroom →, LifeX VenturesDealroom has a profile for this one. Try Dealroom →, Everywhere VenturesDealroom has a profile for this one. Try Dealroom →, UNQDealroom has a profile for this one. Try Dealroom →, 51 Ventures, Cistern CapitalDealroom has a profile for this one. Try Dealroom →, and NIAN Sports & Entertainment, alongside angels including Dr. Jorge Planas and former H&MDealroom has a profile for this one. Try Dealroom → president Daniel Kulle.
What's the endgame? The startup sells a membership that analyses blood biomarkers to flag health risks before symptoms appear. Its core plan, Axo Longevity Care, costs €490 a year and includes two panels of 100-plus biomarkers each, a health score, biological age, and personalised plans; membership starts at €190 a year.
Why now? Axo Longevity moved from build to live operations in 12 weeks. It now runs in the UK, Ireland, Spain, Germany, the Netherlands, and Peru, drawing on more than 1,400 laboratory locations through partners including RandoxDealroom has a profile for this one. Try Dealroom → and EurofinsDealroom has a profile for this one. Try Dealroom →. More than 19,000 people have joined its waitlist.
What will the money do? The funding will grow the laboratory network, develop an AI health copilot and wearable integrations, and expand into the Nordics, Italy, and Portugal, said co-founder and chief product and growth officer Sergio Tang.
The company frames Europe's clinical infrastructure as strong but hard to access. "Europe has exceptional clinical infrastructure, but for consumers it is fragmented, and they might only be able to access it when they are sick," Tang said. Members retest after six months to track changes against optimal ranges rather than population averages.
What could go wrong? Consumer health startups often stumble on execution, not science. "Consumer health companies usually fail on operations, not on science," said Jon Soberg, chief executive officer and managing partner of MS&AD Ventures, pointing to the difficulty of running across six markets versus a single launch.
The signal: The round sits in roughly the 36th percentile by size, a modest seed in a crowded longevity field. Axo Longevity’s bet is that operational reach — a live lab network and returning members — matters more than a single-market debut as preventive health moves toward recurring, data-driven memberships.
Read more: rutlandherald.com
Image credit: Axo Longevity
